Cullgen is a biopharmaceutical company that has developed protein degradation technology that utilizes the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Our technology, which we call uSMITE™ (ubiquitin-mediated, small molecule-induced target elimination) has the potential to address a broad range of intracellular disease targets, including those representing the up to 80% of proteins that cannot be addressed by existing small molecule therapies, commonly referred to as undruggable targets. In addition to using our uSMITE™ platform to build our own pipeline of protein degradation product candidates, we are also developing a portfolio of novel E3 ligands. You can learn more information about Cullgen on our website: www.Cullgen.com
Company Details
- Employees
- 30
- Founded
- -
- Address
- 12730 High Bluff Dr,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.cullgen.com
- HQ
- San Diego, California
Cullgen Inc. Questions
Cullgen Inc.'s website is http://www.cullgen.com
Cullgen Inc.'s LinkedIn profile is https://www.linkedin.com/company/cullgen
Cullgen Inc. has
30 employees.
View email and phone details for 30
employees at Cullgen Inc..
Cullgen Inc.'s industry is
Biotechnology Research
Cullgen Inc.'s top competitors are
Genalyte, Inc.,
Intrabio Inc,
Belharra Therapeutics,
Pulmatrix Inc.,
Avidity Biosciences, Inc.,
Biosapien,
Crinetics Pharmaceuticals,
Gyre,
Primmune Therapeutics,
Trefoil Therapeutics.
Cullgen Inc.'s categories are Biotechnology Research
Cullgen Inc.'s founding year is 2018
